Craft

Mirati Therapeutics

Revenue

$12.4 M

FY, 2022

Mirati Therapeutics Summary

Company Summary

Overview
Mirati Therapeutics is an oncology company that designs and develops targeted therapies to address the genetic drivers of cancer. It provides Kirsten RAT sarcoma virus (KRAS) and methylthioadenosine-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor programs.
Type
Subsidiary
Status
Active
Founded
2013
HQ
San Diego, CA, US | view all locations
Website
https://mirati.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Charles Baum
  • James Christensen

    James Christensen, CSO and EVP, Research

  • Ben Hickey

    Ben Hickey, Chief Commercial Officer, Head of Business Development

  • Alan Sandler

    Alan Sandler, EVP, Chief Medical Officer

Operating MetricsView all

Molecules

1K

FY, 2021

Manufacturing Space, sq. ft.

118K
181.0%

FY, 2021

LocationsView all

2 locations detected

  • San Diego, CA HQ

    United States

    3545 Cray Court

  • Zug, ZG

    Switzerland

    Dammstrasse 19

Mirati Therapeutics Financials

Summary Financials

Revenue (Q3, 2023)
$16.4M
Gross profit (Q3, 2023)
$14.7M
Net income (Q3, 2023)
($161.9M)
Cash (Q3, 2023)
$258.7M
EBIT (Q3, 2023)
($172.1M)

Footer menu